Introduction to Circulating Tumor DNA
Plasma DNA or cell-free DNA (cfDNA) 3 is fragmented, extracellular DNA collected noninvasively by liquid biopsy, and used to detect circulating fetal DNA in pregnant women or tumor DNA in cancer patients. Tumor apoptotic and necrotic cells are digested mainly by phagocytes, and cell debris including nuclear material such as DNA is released into the circulation. Host cfDNA fragments are between 143 bps and 166 bps (1, 2 ) ; some studies suggest that tumor-derived cfDNA is shorter than normal cfDNA (as exemplified by comparisons of the fragment length of DNA harboring mutant with wild-type alleles); this difference introduces the opportunity to enrich tumor DNA by size selection-based approaches (3) (4) (5) . Moreover, specific patterns in plasma DNA length can inform on cfDNA nucleosome occupancies that correlate with the nuclear architecture, gene structure, and expression observed in cells, suggesting that this information could be used to identify what cell type cfDNA originated from (6, 7 ) . Intact tumor cells can also be detected in circulation in advanced cancer patients (i.e., circulating tumor cells, CTCs), and these have been proposed as a source of plasma DNA. There is a correlation between the number of CTCs and the amount of circulating tumor DNA in metastatic prostate cancer (8 ) ; however, tumor DNA equivalent to several 100 to 1000s of genomes is routinely extracted from 10 mL of blood from men with advanced prostate cancer in which fewer than 10 CTCs are detected. This difference could be a result of CTC capture efficiency by current technologies or more rapid degradation of CTCs but could also suggest different mechanisms of release.
The early clinical application of cfDNA was in fetal medicine to detect aneuploidy such as trisomy 21 and other congenital disorders (9 ) . Similarly, circulating tu-mor DNA (ctDNA) or plasma tumor DNA in cancer patients can be quantified and characterized (10 ) . This capability could be important because acquiring tissue from metastatic sites, especially repeatedly, is challenging, and tissue biopsies may fail to represent the genomic landscape of multiple metastases. Therefore, liquid biopsies can provide a solution to noninvasively profile a cancer's genome in real time, improving monitoring of treatment response, detection, and interrogation of disease recurrence and molecularly driven treatment prediction. Also, with improved sensitivity, early detection of cancer could become possible. Plasma DNA, given its relatively uniform fragment size, is amenable to next-generation sequencing, and the main challenges in its analysis compared to tissue studies are the relatively low DNA inputs (approximately 10 -20 ng/mL) and variable tumor DNA fraction (Ͻ1% to Ͼ90%). These 2 factors are linked: as more tumor DNA enters circulation, both the tumor-tonormal fraction and the total amount of DNA that is extracted per milliliter of plasma increase. Overall, the proportion of plasma DNA that is tumor in origin varies by tumor volume, sites, number of metastases, disease status, and cancer biology. A report from the TRACERx study, a multicenter, multiregion sequencing project to interrogate lung tumor evolution, has demonstrated that radiologically defined primary non-small cell lung cancer volume is associated with mean clonal variant allelic frequency (VAF), an indicator of circulating tumor DNA fraction; for example, a volume of 10 cm 3 predicted a VAF of 0.1% (11 ) . Moreover, the presence of plasma tumor DNA was associated with different histopathological subtypes. For example, in stage I non-small cell lung cancer, ctDNA was detected in Ͼ90% of squamous cell carcinomas, compared to Ͻ20% in adenocarcinomas (11 ) . Analysis of earlier stage patients may therefore require a combinatorial approach of larger blood volumes and more sensitive assays. For example, amplicon-based or customized target enrichment using improved biochemistry of random molecular barcoding and optimized, error-correcting analysis on ultradeep sequencing (i.e., Ͼ10000ϫ) can potentially improve the sensitivity of rare mutation and indel detection on ctDNA (12) (13) (14) (15) .
Epigenetic information, such as DNA methylation change, can be extracted from plasma DNA with modified next-generation sequencing protocols to obtain information additional to the genomic status (16 ) . DNA methylation, the addition of a methyl group to cytosine, is a modification that occurs at thousands of sites across the genome and is tissue-of-origin and cancer specific. This information can therefore be exploited for cancer detection, diagnosis of tumor type, estimation of tumor cfDNA fraction, and assessment of treatment response (17, 18 ) . For example, a pilot study has shown detec-tion of GSTP1 4 methylation in blood was prognostic and could be used as a response marker in metastatic castration-resistant prostate cancer (mCRPC) (19 ) . In colorectal cancer, several individual methylation markers, such as exon 1 of the vimentin gene, have been tested in plasma DNA for diagnostic purpose (20, 21 ) . Additionally, targeted sequencing of informative CpG methylation markers in hepatocellular carcinoma has shown high diagnostic fidelity (22 ) . Epigenetic information could also potentially be integrated with genomic analyses to improve the clinical utility of liquid biopsies.
Multiple technologies are converging to accelerate the development of a ctDNA clinical test. This development includes the optimization of preanalytical factors involved in sample collection, including plasma collection tubes that minimize ex vivo leukocyte degradation (that presents as fragments Ͼ1000 base pairs in length and can interfere with quantification, analysis, and VAF or copy number assessment owing to dilution of tumor DNA) and minimize intersample variability. Nextgeneration sequencing (NGS) of whole genomes or exomes has been optimized for research purposes, but most tests for clinical use are focused on selected recurrent and informative targets, and include either custom NGS panels covering hot-spot mutations and copy number aberrations or targeted approaches such as droplet digital PCR and the use of beads, emulsions, amplification, and magnetics (BEAMing) (23) (24) (25) (26) . Droplet digital PCR and BEAMing may be more economical and more amenable to high-sensitivity testing and have a more rapid turnaround than targeted NGS. However, the limited number of targets tested could limit their broader applicability. ctDNA as a liquid biopsy is currently limited by several inherent challenges. First, information related to protein, messenger RNA, and other epigenetic modifiers, such as histone methylation or acetylation, will be missed, and approaches to capture the information could improve the value of blood analyses relative to tissue. Secondly, plasma DNA is a mixture of tumor DNA from different clones and/or metastatic sites, and it is unclear whether it is possible to determine the metastatic site of origin or the relative contribution of individual metastases. This complication creates challenges for interrogating the subclonal architecture and rare, private genomic lesions at the resolution achieved with intact cell analysis. Third is the fact that variable contributions from normal tissue DNA also introduce interpatient and sample differences and lead to a requirement for higher sensitivity approaches.
Molecular Characterization of Circulating Tumor DNA in Prostate Cancer
Prostate cancer is a highly heterogeneous disease with variable clinical outcomes. Several recurrent genomic changes have been reported either in isolation or in combination to improve prognostication or prediction of response to therapy of an individual's cancer. Detection of copy number alterations from primary prostate tumor samples has been shown to be a strong prognostic indicator linked with more aggressive disease and increased risk of relapse after local intervention (27 ) . More recently, comprehensive analysis of localized prostate cancer identified additional DNA methylation markers, along with genetic aberrations, as being strongly linked with disease recurrence (28 ) . In metastatic disease, detection in plasma DNA of genomic alterations involved in specific pathways could allow molecularly driven treatment selection, especially for the majority of patients for whom tumor tissue is not available or is of insufficient quality.
Estimating Tumor Fraction
Given the highly variable admixture of tumor-to-normal DNA, estimation of tumor fraction is a key first step to characterizing the tumor genomic landscape. Detection of copy number changes requires plasma tumor DNA fractions above a critical threshold. Interrogating resistance needs recognition of the tumor-driven denominator. Conceptually, to estimate ctDNA fraction, one can track a genomic change that occurs early in carcinogenesis (prebranching) and is therefore present in every cancer cell in that individual. In several cancers, the allelic frequency of common and recurrent hot-spot point mutations has been used to track tumor DNA (29, 30 ) . Proof-of-concept analyses in metastatic breast cancer have used structural variant or somatic mutations identified in tumor tissues, and applied droplet digital PCR or amplicon-based targeted deep sequencing to quantify and define circulating tumor DNA contents (29 ) . This technique could be further optimized and personalized to track patient-specific mutations identified by multiregional sequencing (11 ) . Prostate cancer does not have commonly recurrent, clonal point mutations and thus requires a broader approach. One strategy is to quantify a panel of genomic changes that have occurred at an early stage of prostate cancer and if truncal events would be present in all metastasizing cells. Two such events that could be used to track tumor content in prostate cancer are monoallelic deletions associated with ETS gene family rearrangements (primarily involving the oncogenes ERG or ETV1 that fuse with an androgen-regulated promoter) and NKX3-1 deletion on chromosome 8p, strongly linked with prostate cancer development. Ei-ther alteration occurs in Ͼ50% of advanced prostate cancer patients and has been shown to be clonal in mCRPC (31, 32 ) . Because coverage estimations for quantitating monoallelic deletions are unreliable in plasma samples with relatively lower tumor fractions, alternative approaches such as leveraging information of germline heterozygous single nucleotide polymorphisms could be used to measure tumor reads harboring the deletions (8 ) .
Another approach is to estimate tumor fraction with VAF from mutation calls in whole-exome or very broad targeted NGS (33 ) . This approach requires adjustment for loss of heterozygosity for every mutation call or a conservative assumption that loss of heterozygosity cooccurs with all mutations. It could underestimate tumor fraction if loss of heterozygosity is assumed when it is not present or conversely overestimate if a mutation is in an amplified region. The accuracy of using deletions or mutations to quantify tumor fraction will depend on that aberration being present in all, or at least the majority, of clones represented in circulation; emergence of a clone that harbors aberrations not included in the data will be missed. A third strategy is to use the magnitude of genome-wide copy number aberrations to estimate tumor fraction. This approach could be especially suited for advanced prostate cancer characterized by high copy number alterations (34 ) . Shallow WGS can be used to estimate copy number alterations, and widely implemented across plasma samples but may not be amenable to detect tumor fractions below 8%-10%, and it can serve as a triage to select samples with higher tumor fraction applicable for further analysis (35 ) .
Plasma DNA-Based Molecular Stratification
Analysis of plasma DNA from mCRPC patients shows similar prevalence of major genomic subtypes as in tissue studies (33 ) . These subtypes include somatic mutations in TP53 (42%-56%), AR (10%-15%), APC (8%-12%), and PTEN (6%-10%). Systematic comparison of targeted sequencing data from liquid biopsy and tissue has shown a high degree of concordance with multiple shared mutations (usually the most abundant in both biopsy and plasma), mutations restricted to plasma tumor DNA (putatively private to metastases that were not biopsied), and less abundant mutations private to the biopsied metastasis not detected in plasma tumor DNA (the latter could be reduced by increasing the sensitivity of ctDNA assays) (36 ) . This finding is important for future plasma DNA clinical implementation because most of the drivers or actionable lesions can be detected from circulation in mCRPC patients.
The androgen receptor gene (AR) is very rarely detected as mutated or gained in cancers that have not be-come resistant to endocrine therapies but is aberrant in 30%-50% of mCRPC. Obtaining tissue biopsies from men immediately at development of mCRPC is challenging because of the low metastatic volume and tumor biopsies that may miss AR-gained subclone. Analysis of plasma DNA has been used to identify AR copy number gain or somatic point mutations across the mCRPC spectrum. Many point mutations have been identified in plasma tumor DNA, including AR c.2226 GϾT associated with a W742C amino acid change that results in bicalutamide becoming an agonist and that is often detected after bicalutamide discontinuation and initiation of the next line of effective treatment (8, 37 ) . Detection of AR copy number gain or one of the 2 most common and functionally relevant mutations (AR c.2105TϾA and c.2632AϾG resulting in L702H and T878A amino acid changes, respectively) in plasma before initiation of treatment with the second-line endocrine agents abiraterone or enzalutamide is strongly associated with worse outcome (25, 33, 38 ) . Interestingly, an L702H change results in activation by glucocorticoids (including prednisone) and has only been detected in patients previously treated with prednisone (8 ) . In contrast, AR aberrant patients receiving taxanes do not have a worse outcome than AR normal, introducing the opportunity to select mCRPC patients for AR targeting drugs vs taxanes on the basis of ctDNA analysis (39 ) . A similar observation has been made for AR splice variants lacking ligand-binding domain, and composite biomarkers that assess AR messenger RNA, gene, and protein could improve prediction of resistance to abiraterone or enzalutamide (40 ) . More recently, studies have reported that TP53 aberrations are associated with a worse outcome that is independent of tumor fraction, AR aberrations, and other variables (41 ) . The detection of circulating tumor biomarkers is more likely as tumor fraction increases: this change could introduce a bias of higher tumor fraction (associated with worse prognosis) contributing to the observation of worse outcome (38 ) .
Plasma DNA analysis could also explain mechanisms of resistance through analysis of sequential samples identifying genomic changes associated with emergent clones. This approach identified emergence or an increased VAF of the aforementioned L702H and T878A amino acid changes in progression samples from mCRPC patients treated with abiraterone (in combination with prednisone) (38 ) . PARP inhibition is being clinically evaluated in mCRPC patients with an underlying DNA-repair gene defect. Plasma DNA analysis of pretreatment and progression samples from patients treated with PARP inhibitors has identified multiple (even in a single patient) reversion BRCA2 mutations that restore protein function and lead to resistance to PARP inhibitors (42, 43 ) . These genomic changes that are associated with resistance are often detected in plasma DNA before clinical or radiological progression and could allow earlier treatment change. Also, it appears that more mutations are detected in plasma than in a matched tumor biopsy.
Translational Application of ctDNA in Prostate Cancer
Although ctDNA analysis has the potential for improving patient care, there is presently no plasma-based test that is supported by level 1 evidence for implementation into clinical practice in prostate cancer management. Here we highlight applications in different tumor types and discuss their potential role in prostate cancer clinical management (Fig. 1) .
Early Detection of Prostate Cancer
Cancer detection and diagnosis at a presymptomatic stage could radically improve cancer mortality rates but remain challenging. Improved screening of men for prostate cancer will have major public health benefits: current practices using prostate-specific antigen (PSA) result in overdiagnosis of nonlethal disease and overtreatment of several thousand men every year (44 ) . Diffusionweighted pelvic MRI and targeted screening of germline genetic high-risk men are strategies being explored, in combination with PSA, to minimize false-positive detection rate (45) (46) (47) .
The major challenges for a plasma DNA test in this setting are as follows: balancing high specificity and sensitivity in detecting plasma tumor DNA, low ctDNA abundance, and the lack of prior information on the unique molecular features of each individual tumor. In general, cancer screening needs to reflect cell of origin to inform clinicians on actionable plans. Different tumors harbor distinct methylation features, and most changes are tissue-specific. "CancerLocator" uses methylation status from low-coverage whole-genome bisulfite sequencing on plasma DNA from lung, breast, and colorectal cancer patients and healthy volunteers to identify undiagnosed tumors (17 ) . Similar approaches using a custom targeted panel to capture informative CpG sites in hepatocellular carcinoma also showed promising results for cancer detection in patients with liver diseases (22 ) . Targeted error correction sequencing was developed also to address the technical hurdle of rare genomic alteration detection without prior tumor information (13 ) . An ongoing prospective, multicenter trial (Clinical Trial.gov Identifier: NCT02889978) commercially sponsored by GRAIL aims to systematically tackle the challenges of early diagnosis by large-scale, multicenter plasma collection and centralized analysis by using NGS-based approaches (48 ) . Tests for early cancer detection, especially of nonindolent aggressive disease, will need to minimize over-treatment and balance the risks of unnecessary anguish for men who do not require further treatment. This test could be targeted at specific groups, for example based on germline risk factors.
Risk Stratification and Detection of Minimal Residual Disease and Relapse
Detection of ctDNA shortly after surgical resection or radiotherapy treatment to the primary could be used to stratify patients who require additional systemic treatment. The feasibility of this has been shown in multiple cancer types, including breast, colorectal, and lung tumors; these studies suggest that ctDNA detected shortly after surgery more sensitively predicts tumor relapse than currently used clinicopathological parameters: the risk for relapse in individuals with ctDNA-positive compared to ctDNA-negative samples has been reported as Ͼ6-fold in multiple studies across tumor types (11, 30, 49 ) . This finding could have important utility in prostate cancer, in which the risk of relapse is highly variable and could allow selection of adjuvant systemic treatment for the relatively low proportion of patients who would derive maximum benefit. A number of randomized clinical trials in this setting are collecting plasma to evaluate the relationship of ctDNA with treatment response and long-term benefit (examples: ClinicalTrial.gov Identifiers NCT01411332 and NCT01411345). Similarly, analysis of sequential samples from men in follow-up could detect early relapse and avoid life-prolonging treat-ment. In these clinical settings, plasma DNA analysis would have to improve on, alone or in combination, serum PSA readings.
Prediction of Treatment Outcome and Response Assessment in Metastatic Disease
The first plasma-based test to receive approval from the regulatory authorities for clinical use in cancer patients is the Cobas EGFR Mutation test used to identify EGFR mutations, exon 19 deletion, or exon 20 insertions for the selection of patients with metastatic non-small cell lung cancer who stand to benefit from EGFR-targeted therapy.
In mCRPC, mismatch repair deficiency occurs in Ͻ2% of patients (50, 51 ) ; given that immunotherapy has shown increased efficacy and PD1 blockade has received regulatory approval for use in this molecularly defined subgroup of patients, there is an indication to test for MMR gene defects in mCRPC patients (52 ) . DNA repair gene aberrations are more common, occurring in up to 20% of mCRPC patients. Ongoing trials are selecting mCRPC patients with an underlying germline or somatic DNA-repair defects for treatment with agents targeting DNA-repair mechanisms, most notably PARP inhibitors (53 ) . Most trials are using archival formalinfixed paraffin-embedded tissue or a fresh tissue biopsy for patient selection. Major efforts are underway to concurrently develop a ctDNA-based test. The main challenge remains the accurate detection of monoallelic (in combination with pathogenic deactivating mutations) and bi- allelic deletions in ctDNA with a highly variable and often low (Ͻ0.1) tumor-to-normal fraction. Given that CRPC metastases primarily involve bone, quantitative imaging assessment of response or early progression is challenging. Serum PSA is often used in clinical practice to guide decisions on continuing or stopping treatment for disease progression. However, given PSA expression is exquisitely androgen regulated, absolute concentrations and changes may not entirely reflect disease behavior and in fact PSA has not met the requirements for a surrogate biomarker of overall survival (54 ) . CTC dynamics have been shown to strongly associate with treatment benefit across multiple therapeutic strategies. Comprehensive evaluation of CTC change before and after the treatment indicated that a drop in CTC number in week 13 is strongly linked with prolonged survival (54 ) . These results are encouraging for liquid biopsy assessment in this setting, but the absence of and costs for detection of CTC could limit this application in earlier disease states. ctDNA change in metastatic breast cancer reflective of treatment response had superior sensitivity to CTC and CA15-3 (29 ) . Preliminary data in mCRPC indicated that plasma DNA change in sequential plasma samples from mCRPC reflects treatment response (43 ) . Future studies could further assess this.
Combinations with Other Modalities
A constellation of other emerging circulating biomarkers such as circulating tumor cell (CTC), circulating micron RNA (miRNA), and extracellular vesicles (EVs) have shown potential for future clinical translation. CTC can be detected and isolated with different technologies, but the challenge of detecting rare intact cells could limit implementation of CTC analysis in patients with lower tumor volume. Combination biomarkers that analyze both ctDNA and CTC could have higher resolution than ctDNA alone, especially because they can study expression. A recent example is the combined analysis of AR aberrations including genomic aberrations in plasma DNA and increased AR splice variant messenger RNA expression or nuclear protein expression in CTC (40 ) (55 ) . Circulating miRNAs, short noncoding RNAs released into the circulation, are known to be resistant to RNase digestion and could be quantified in prostate cancer for diagnostic and prognostic purposes (56 -58 ) . EVs contain tumor material and can be another source of cancer-specific information in the circulation. Early findings reveal genetic aberrations specific to metastatic prostate cancer in large EVs (59 ) . It is possible that these circulating tumor markers (CTC, circulating miRNA, EVs) could be integrated with plasma DNA analysis to facilitate better clinical decisions.
Conclusion
Plasma DNA analysis reports in prostate cancer have to date shown promising clinical utility in cohorts in which the aims of analyses were defined after sample collection or prospectively but did not influence treatment. Also, most studies have been performed with tests conducted in a research setting in specialist laboratories. Implementation of a test into clinical practice requires level 1 evidence that prospectively demonstrates improved outcomes as a result of testing. This implementation requires an analytically validated assay that is fit for purpose, a clinical question that needs addressing, strong biological supporting data and clinical associations shown in retrospective studies, and prospective trials where the test is implemented in the predefined patient population.
